← Back to headlines
Janux Halts Development of Tumor-Activated T Cell Engager Drug
Biopharmaceutical company Janux Therapeutics has announced the discontinuation of its Tumor Activated T Cell Engager asset, impacting its drug development pipeline.
27 Apr, 20:36 — 27 Apr, 20:36
Sources
Showing 1 of 1 sources
Related Stories
Experts warn of worsening health crisis in Nigeria due to plastic pollution
just now
Dermatologists warn of rising skin cancer cases linked to bleaching creams
just now
Doctors caution against using petrol, kerosene for motion sickness
just now
First teenage suicide in England and Wales linked to domestic abuse
20m ago